Form 4: Zimmer Biomet Executive Rachel Ellingson Reports Stock Transactions

Rachel Ellingson, SVP & Chief Strategy Officer of Zimmer Biomet, reports the vesting of restricted stock units and subsequent transactions involving common stock.

Summary

• On March 6, 2024, Rachel Ellingson, SVP & Chief Strategy Officer of Zimmer Biomet Holdings, Inc., reported transactions involving the company's common stock.
• 1,419 shares were acquired through the vesting of restricted stock units (RSUs).
• 445 shares were disposed of to cover tax withholding obligations at a price of $125.82 per share.
• Following these transactions, Ellingson directly owns 6,846 shares of Zimmer Biomet common stock and 2,837 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The remaining RSUs vest in two tranches: one-half on March 6, 2025, and the final one-half on March 6, 2026.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock. This filing indicates standard compensation practices involving RSUs and tax withholding.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they represent standard executive compensation and tax obligations.

Key Dates